Clinical Trial Update: Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) [Phase 3]

View source ↗

Summary

A Phase 3 trial (MK-3475-630/KEYNOTE-630) evaluating pembrolizumab versus placebo after surgery and radiation in locally advanced cutaneous squamous cell carcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Squamous Cell | Phase 3 | Status: COMPLETED | Results posted: 2025-07-22